VINCRISTINE HOSPIRA 2 mg/2 ml

RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome

MARSUN: Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma